Merck (MRK) Stock Dips While Market Gains: Key Facts

In the latest close session, Merck (MRK) was down 1.95% at $121.41. This move lagged the S&P 500's daily gain of 0.04%. Meanwhile, the Dow experienced a drop of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.36%. Shares of the pharmaceutical company have appreciated by 12.29% over the course of the past month, outperforming the Medical sector's gain of 0.92%, and the S&P 500's loss of 1.33%.Market participants will be closely following the financial results of Merck in its upcoming release. It is anticipated that the company will report an EPS of -$0.41, marking a 118.47% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $16.01 billion, reflecting a 3.09% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.5 per share and revenue of $66.68 billion, indicating changes of -38.75% and +2.57%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 17.16% lower within the past month. Merck is currently sporting a Zacks Rank of #4 (Sell). From a valuation perspective, Merck is currently exchanging hands at a Forward P/E ratio of 22.53. This valuation marks a premium compared to its industry average Forward P/E of 16.02. We can additionally observe that MRK currently boasts a PEG ratio of 2.24. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. MRK's industry had an average PEG ratio of 2.33 as of yesterday's close. The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 172, this industry ranks in the bottom 30% of all industries, numbering over 250. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.See Our Newest 5 Stocks Set to Double Picks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks